Sample size calculations in randomised trials: mandatory and mystical

[1]  K. Schulz,et al.  Multiplicity in randomised trials II: subgroup and interim analyses , 2005, The Lancet.

[2]  S. Piantadosi.  Clinical Trials : A Methodologic Perspective , 2005 .

[3]  A. Hrõbjartsson,et al.  Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. , 2004, JAMA.

[4]  Gerd Antes,et al.  Under-reporting of clinical trials is unethical , 2003, The Lancet.

[5]  R. Lilford.  The ethics of underpowered clinical trials. , 2002, JAMA.

[6]  J. Karlawish,et al.  The continuing unethical conduct of underpowered clinical trials. , 2002, JAMA.

[7]  Mike Clarke,et al.  Discussion sections in reports of controlled trials published in general medical journals. , 2002, JAMA.

[8]  Kenneth F Schulz,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Trialists Rely on the Security of Unpredictability. in the Forcing Cosmetic Credibility Unequal Group Sizes in Randomised Trials: Guarding against Guessing , 2022 .

[9]  Kenneth F Schulz,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Exclusions before Randomisation Exclusions after Randomisation Sample Size Slippages in Randomised Trials: Exclusions and the Lost and Wayward , 2022 .

[10]  I. Chalmers.  Cardiotocography v Doppler auscultation. All unbiased comparative studies should be published. , 2002, BMJ.

[11]  Kenneth F Schulz,et al.  Blinding in randomised trials: hiding who got what , 2002, The Lancet.

[12]  Kenneth F Schulz,et al.  Allocation concealment in randomised trials: defending against deciphering , 2002, The Lancet.

[13]  Kenneth F Schulz,et al.  Generation of allocation sequences in randomised trials: chance, not choice , 2002, The Lancet.

[14]  Y Tsong,et al.  Group sequential test strategies for superiority and non‐inferiority hypotheses in active controlled clinical trials , 2001, Statistics in medicine.

[15]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Annals of internal medicine.

[16]  D. Moher,et al.  The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.

[17]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[18]  W. Lehmacher,et al.  Adaptive Sample Size Calculations in Group Sequential Trials , 1999, Biometrics.

[19]  Sue-Jane Wang,et al.  Modification of Sample Size in Group Sequential Clinical Trials , 1999, Biometrics.

[20]  R. Peto.  Failure of randomisation by “sealed” envelope , 1999, The Lancet.

[21]  David Braunholtz,et al.  Why “underpowered” trials are not necessarily unethical , 1997, The Lancet.

[22]  K. Dickersin.  How important is publication bias? A synthesis of available data. , 1997, AIDS education and prevention : official publication of the International Society for AIDS Education.

[23]  D G Altman,et al.  Absence of evidence is not evidence of absence. , 1996, Australian veterinary journal.

[24]  J G Thornton,et al.  Clinical trials and rare diseases: a way out of a conundrum , 1995, BMJ.

[25]  K. Schulz,et al.  Subverting randomization in controlled trials. , 1995, JAMA.

[26]  J. Peipert,et al.  Sample size and statistical power in reproductive research. , 1995, Obstetrics and gynecology.

[27]  P. Fayers,et al.  Sample size: how many patients are necessary? , 1995, British Journal of Cancer.

[28]  I. Chalmers.  What do I want from health research and researchers when I am a patient? , 1995, BMJ.

[29]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[30]  J. Matthews,et al.  Small clinical trials: are they all bad? , 1995, Statistics in medicine.

[31]  S. Goodman,et al.  The Use of Predicted Confidence Intervals When Planning Experiments and the Misuse of Power When Interpreting Results , 1994, Annals of Internal Medicine.

[32]  D L Sackett,et al.  Can We Learn Anything from Small Trials? , 1993, Annals of the New York Academy of Sciences.

[33]  Peter Sleight,et al.  Data-monitoring committees in clinical trials , 1993, The Lancet.

[34]  D. Grimes,et al.  Preventing IUCD‐related pelvic infection: The efficacy of prophylactic doxycycline at insertion , 1991, British journal of obstetrics and gynaecology.

[35]  S. Sinei,et al.  Preventing IUCD‐related pelvic infection: the efficacy of prophylactic doxycycline at insertion , 1990 .

[36]  I Chalmers,et al.  Underreporting research is scientific misconduct. , 1990, JAMA.

[37]  J. Wittes,et al.  The role of internal pilot studies in increasing the efficiency of clinical trials. , 1990, Statistics in medicine.

[38]  M. D. Walker.  ATRIAL FIBRILLATION AND ANTITHROMBOTIC PROPHYLAXIS: A PROSPECTIVE META-ANALYSIS , 1989, The Lancet.

[39]  L. Bolognese,et al.  RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.

[40]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[41]  B. Rodda,et al.  Clinical trials: Design, conduct, and analysis , 1987 .

[42]  K. Dickersin,et al.  Publication bias and clinical trials. , 1987, Controlled clinical trials.

[43]  T C Chalmers,et al.  Meta-analysis of clinical trials as a scientific discipline. I: Control of bias and comparison with large co-operative trials. , 1987, Statistics in medicine.

[44]  A. Detsky,et al.  When was a "negative" clinical trial big enough? How many patients you needed depends on what you found. , 1985, Archives of internal medicine.

[45]  S. Pocock,et al.  Clinical Trials: A Practical Approach , 1984 .

[46]  T C Chalmers,et al.  The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. , 1978, The New England journal of medicine.

[47]  E. Veys,et al.  HL-A AND INFECTIVE SACROILEITIS , 1974 .

[48]  J. Wilkinson,et al.  TREATMENT OF ACUTE LEUKÆMIA WITH AMINOPTERIN , 1951 .